Table of contents

Electronic pages

• Correspondence on ‘Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement’ (4 March, 2021) Free

  Aaqib Zaffar Banday, Ankur Kumar Jindal, Surjit Singh
• Response to: ‘Correspondence on ‘Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement’’ by Banday et al

  (4 March, 2021) Free

  Peter Nash, Josef S Smolen
• Correspondence on ‘EULAR recommendations for the management of antiphospholipid syndrome in adults’ (23 February, 2021) Free

  Rui Gao, Lang Qin
• Response to: ‘Correspondence on ‘EULAR recommendations for the management of antiphospholipid syndrome in adults’’ by Gao and Qin (23 February, 2021) Free

  Maria G Tektonidou, Angela Tincani, Michael M Ward
• Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’ (15 February, 2021)

  Pierre Charles
• Response to: ’Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’’ by Charles (15 February, 2021)

  Sofia Ramiro, Rémy L M Mostard, Robert B M Landewé
• Response to: ‘Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’’ by Charles (3 March, 2021) Free

  Josef S Smolen
• Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’ (16 February, 2021)

  Maria De Santis, Antonio Voza, Victor Savevski, Salvatore Badalamenti, Maurizio Cecconi, Alberto Mantovani, Carlo Selmi
• Response to: ‘Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’’ by De Santis et al

  (16 February, 2021)

  Sofia Ramiro, Rémy L M Mostard, Robert B M Landewé
• Correspondence on ‘Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry’ (18 February, 2021)

  Laurent Arnaud, Hervé Devilliers
• Response to: ‘Correspondence on ‘Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry’ by Arnaud and Devilliers (18 February, 2021)

  Pedro M Machado, Martin Schäfer, Anja Strangfeld, Laure Gossec, Milena Gianfrancesco, Saskia Lawson-Tovey, Elsa F Mateus, Loreto Carmona, Kimme L Hyrich, Philip C Robinson, Jinoos Yazdany
• Correspondence on ‘Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry’ (1 March, 2021)

  Ben Mulhearn
• Response to: ‘Correspondence on ‘Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry’’ by Mulhearn et al

  (1 March, 2021)

  Martin Schäfer, Anja Strangfeld, Kimme L Hyrich, Loreto Carmona, Milena Gianfrancesco, Saskia Lawson-Tovey, Elsa F Mateus, Laure Gossec, Philip C Robinson, Jinoos Yazdany, Pedro M Machado
• Comment on ‘Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19’ by Konig et al. Long-term exposure to hydroxychloroquine or chloroquine and the risk of hospitalisation with COVID-19: a nationwide, observational cohort study in 54 873 exposed individuals and 155 689 matched unexposed individuals in France

  (28 August, 2020)

  Emilie Sbidian, Laetitia Penso, Philippe Herlemont, Jérémie Botton, Bérangère Baricault, Laura Semenzato, Jérome Drouin, Alain Weill, Rosemay Dray-Spira, Mahmoud Zureik
• Paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS): what does the future hold? (15 September, 2020)

  Murugan Sudhakar, Pandiarajan Vignesh
• Correspondence on ‘Disease activity, cytokines, chemokines and the risk of incident diabetes in rheumatoid arthritis’ (22 February, 2021) Free

  Piero Ruscitti, Giorgio Sesti, Paola Cipriani, Roberto Gerli, Roberto Giacomelli
• Response to: ‘Correspondence on ‘Disease activity, cytokines, chemokines and the risk of incident diabetes in rheumatoid arthritis’’ by Ruscitti et al

  (22 February, 2021) Free

  Joshua F Baker, Bryant R England, Ted R Mikuls
• Correspondence on ‘MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group’ (3 March, 2021) Free

  Zaid Jibri, Ummugulsum Gazel, Dilek Solmaz, Gizem Ayan, Jacob Karsh, Sibel Zehra Aydin, Marcos Sampaio
• Response to: ‘Correspondence on ‘MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group’’ by Jibri et al

  (3 March, 2021) Free

  Walter P Maksymowych, Robert GW Lambert, Mikkel Østergaard, Xenofon Baraliakos
• Correspondence on ‘Blood–brain barrier leakage in systemic lupus erythematosus is associated with gray matter loss and cognitive impairment’ (23 February, 2021) Free

  Omer Nuri Pamuk, Sarfaraz Hasni
• Response to: ‘Correspondence on ‘Blood-brain barrier leakage in systemic lupus erythematosus is associated with gray matter loss and cognitive impairment’’ by Pamuk and Hasni (23 February, 2021) Free

  Lyna Kamintsky, Steven D Beyea, John D Fisk, Javeria A Hashmi, Antonina Omisade, Cynthia Calkin, Tim Bardouille, Chris Bowen, Maher Quraan, Arnold Mitnitski, Kara Matheson, Alon Friedman, John G Hanly
• Correspondence on ‘Bowman’s capsule rupture on renal biopsy improves the outcome prediction of ANCA-associated glomerulonephritis classifications’ (5 February, 2021) Free

  Samy Hakroush, Björn Tampe
• Response to: ‘Correspondence on ‘Bowman’s capsule rupture on renal biopsy improves the outcome prediction of ANCA-associated glomerulonephritis classifications’’ by Hakroush and Tampe (5 February, 2021) Free

  Vincenzo L'Imperio, Gisella Vischini, Manuel Ferraro, Fabio Pagni
• Correction: The effect of achieving serological remission on subsequent risk of relapse, end-stage renal disease and mortality in ANCA-associated vasculitis: a target trial emulation study

  (12 April, 2023) Free